Data-driven methods to discover molecular determinants of serious adverse drug events

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 3, 2009, Pages 259-268

  Chiang, A P ^a,b   Butte, A J ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FLUOXETINE; IMATINIB; IRINOTECAN; METHAPYRILENE; METHOTREXATE; PARACETAMOL; RABEPRAZOLE; RAPAMYCIN; SIMVASTATIN; THALIDOMIDE; THIAZIDE DIURETIC AGENT; TRANILAST; TRASTUZUMAB; TUMOR NECROSIS FACTOR; WARFARIN; XIMELAGATRAN;

ADVERSE DRUG REACTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BRAIN TOXICITY; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG INFORMATION; DRUG MECHANISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GENE EXPRESSION; GENE REGULATORY NETWORK; GENETIC VARIABILITY; HEAD AND NECK CANCER; HEALTH CARE PERSONNEL; HUMAN; LIVER TOXICITY; MULTIPLE SCLEROSIS; MYOPATHY; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; RESTENOSIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TOXICITY TESTING; TREATMENT RESPONSE;

ANIMALS; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DRUG TOXICITY; HUMANS; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; PRESCRIPTION DRUGS; RISK FACTORS;

EID: 60349110472     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.274     Document Type: Review

References (79)

1. Lazarou, J., Pomeranz, B.H. & Corey, P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200-1205 (1998).
2. Giacomini, K.M., Krauss, R.M., Roden, D.M., Eichelbaum, M., Hayden, M.R. & Nakamura, Y. When good drugs go bad. Nature 446, 975-977 (2007).
3. Butte, A.J. Translational bioinformatics: coming of age. J. Am. Med. Inform. Assoc. 15, 709-714 (2008).
4. Weinshilboum, R.M. & Sladek, S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32, 651-662 (1980).
5. Evans, W.E. & Johnson, J.A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu. Rev. Genomics Hum. Genet. 2, 9-39 (2001).
6. Pirmohamed, M. & Park, B.K. Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 22, 298-305 (2001).
7. Williams, J.A. et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos. 32, 1201-1208 (2004).
8. Sim, S.C. & Ingelman-Sundberg, M. The human cytochrome P450 Allele Nomenclature Committee web site: submission criteria, procedures, and objectives. Methods Mol. Biol. 320, 183-191 (2006).
9. Higashi, M.K. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690-1698 (2002).
10. Meyer, U.A. Pharmacogenetics and adverse drug reactions. Lancet 356, 1667-1671 (2000).
11. Wei, X., McLeod, H.L., McMurrough, J., Gonzalez, F.J. & Fernandez-Salguero, P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest. 98, 610-615 (1996).
12. Iyer, L. et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. 101, 847-854 (1998).
13. McCarthy, M.I. et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat. Rev. Genet. 9, 356-369 (2008).
14. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678 (2007).
15. Cooper, G.M. et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112, 1022-1027 (2008).
16. Sharma, S.K., Balamurugan, A., Saha, P.K., Pandey, R.M. & Mehra, N.K. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am. J. Respir. Crit. Care Med. 166, 916-919 (2002).
17. O'Donohue, J. et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 47, 717-720 (2000).
18. Link, E. et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N. Engl. J. Med. 359, 789-799 (2008).
19. Konig, J., Seithel, A., Gradhand, U. & Fromm, M.F. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch. Pharmacol. 372, 432-443 (2006).
20. FDA approves Gleevec for leukemia treatment. FDA Consum. 35, 6 (2001).
21. Rowley, J.D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290-293 (1973).
22. Baselga, J. et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/ neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14, 737-744 (1996).
23. Slamon, D.J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
24. Minna, J.D., Girard, L. & Xie, Y. Tumor mRNA expression profiles predict responses to chemotherapy. J. Clin. Oncol. 25, 4329-4336 (2007).
25. Chang, J.C. et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362-369 (2003).
26. Butte, A.J., Tamayo, P., Slonim, D., Golub, T.R. & Kohane, I.S. Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. Proc. Natl. Acad. Sci. USA 97, 12182-12186 (2000).
27. Potti, A. et al. Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 12, 1294-1300 (2006).
28. Liu, C. et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol. Med. 14, 575-581 (2008).
29. Byun, E. et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch. Neurol. 65, 337-344 (2008).
30. Lavedan, C. et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol. Psychiatry (2008); e-pub ahead of print 3 June 2008.
31. Turner, S.T. et al. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension 52, 359-365 (2008).
32. Uhl, G.R. et al. Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch. Gen. Psychiatry 65, 683-693 (2008).
33. Galperin, M.Y. The Molecular Biology Database Collection: 2008 update. Nucleic Acids Res. 36, D2-D4 (2008).
34. Danoff, T.M. et al. A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia. Pharmacogenomics J. 4, 49-53 (2004).
35. Lenzer, J. FDA is incapable of protecting US "against another Vioxx". BMJ 329, 1253 (2004).
36. Hammond, I.W., Gibbs, T.G., Seifert, H.A. & Rich, D.S. Database size and power to detect safety signals in pharmacovigilance. Expert Opin. Drug Saf. 6, 713-721 (2007).
37. Parrish, F., Do, N., Bouhaddou, O. & Warnekar, P. Implementation of RxNorm as a terminology mediation standard for exchanging pharmacy medication between federal agencies. AMIA Annu. Symp. Proc., 1057 (2006).
38. Seger, A.C., Jha, A.K. & Bates, D.W. Adverse drug event detection in a community hospital utilising computerised medication and laboratory data. Drug Saf. 30, 817-824 (2007).
39. Gurwitz, J.H. et al. The incidence of adverse drug events in two large academic long-term care facilities. Am. J. Med. 118, 251-258 (2005).
40. Gandhi, T.K. et al. Adverse drug events in ambulatory care. N. Engl. J. Med. 348, 1556-1564 (2003).
41. Kuehn, B.M. FDA turns to electronic "sentinel" to flag prescription drug safety problems. JAMA 300, 156-157 (2008).
42. Hernandez-Boussard, T. et al. The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledge. Nucleic Acids Res. 36, D913-D918 (2008).
43. Wishart, D.S. et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36, D901-D906 (2008).
44. Waters, M. et al. CEBS - Chemical Effects in Biological Systems: a public data repository integrating study design and toxicity data with microarray and proteomics data. Nucleic Acids Res. 36, D892-D900 (2008).
45. Mattingly, C.J. The comparative toxicogenomics database: a cross-species resource for building chemical-gene interaction networks. Toxicol. Sci. 92, 587-595 (2006).
46. Kanehisa, M. et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res. 36, D480-D484 (2008).
47. Chee, M. et al. Accessing genetic information with high-density DNA arrays. Science 274, 610-614 (1996).
48. DeRisi, J. et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat. Genet. 14, 457-460 (1996).
49. Barrett, T. et al. NCBI GEO: mining tens of millions of expression profiles - database and tools update. Nucleic Acids Res. 35, D760-D765 (2007).
50. Natsoulis, G. et al. The liver pharmacological and xenobiotic gene response repertoire. Mol. Syst. Biol. 4, 175 (2008).
51. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006).
52. Lin, Y.A., Chiang, A., Lin, R., Yao, P., Chen, R. & Butte, A.J. Methodologies for extracting functional pharmacogenomic experiments from international repository. AMIA Ann. Symp. Proc., 463-467 (2007).
53. Weinstein, J.N. et al. An information-intensive approach to the molecular pharmacology of cancer. Science 275, 343-349 (1997).
54. New treatments for colorectal cancer. FDA Consum. 38, 17 (2004).
55. Cetuximab approved by FDA for treatment of head and neck squamous cell cancer. Cancer Biol. Ther. 5, 340-342 (2006).
56. Ross, D.T. et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24, 227-235 (2000).
57. Staunton, J.E. et al. Chemosensitivity prediction by transcriptional profiling. Proc. Natl. Acad. Sci. USA 98, 10787-10792 (2001).
58. Sayers, E.W. et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 37, D5-D15 (2008).
59. Yildirim, M.A., Goh, K.I., Cusick, M.E., Barabasi, A.L. & Vidal, M. Drug-target network. Nat. Biotechnol. 25, 1119-1126 (2007).
60. Huang, R.S., Duan, S., Kistner, E.O., Hartford, C.M. & Dolan, M.E. Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol. Cancer Ther. 7, 3038-3046 (2008).
61. Huang, R.S. et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am. J. Hum. Genet. 81, 427-437 (2007).
62. Duan, S. et al. Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res. 67, 5425-5433 (2007).
63. Lee, J.K. et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc. Natl. Acad. Sci. USA 104, 13086-13091 (2007).
64. Fliri, A.F., Loging, W.T., Thadeio, P.F. & Volkmann, R.A. Analysis of drug-induced effect patterns to link structure and side effects of medicines. Nat. Chem. Biol. 1, 389-397 (2005).
65. Fliri, A.F., Loging, W.T., Thadeio, P.F. & Volkmann, R.A. Biological spectra analysis: linking biological activity profiles to molecular structure. Proc. Natl. Acad. Sci. USA 102, 261-266 (2005).
66. Campillos, M., Kuhn, M., Gavin, A.C., Jensen, L.J. & Bork, P. Drug target identification using side-effect similarity. Science 321, 263-266 (2008).
67. National Library of Medicine. Unified Medical Language System. About the UMLS Resources. 〈http://www.nlm.nih.gov/research/umls/about-umls. html〉.
68. Bodenreider, O. The Unified Medical Language System (UMLS): integrating biomedical terminology. Nucleic Acids Res. 32, D267-D270 (2004).
69. Geisler, S.A. & Olshan, A.F. GSTM1, GSTT1, and the risk of squamous cell carcinoma of the head and neck: a mini-HuGE review. Am. J. Epidemiol. 154, 95-105 (2001).
70. Tokizane, T. et al. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin. Cancer Res. 11, 5793-5801 (2005).
71. Chung, I. et al. Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol. J. Biol. Chem. 282, 8704-8714 (2007).
72. Ruvkun, G. The perfect storm of tiny RNAs. Nat. Med. 14, 1041-1045 (2008).
73. Tsuchiya, Y., Nakajima, M., Takagi, S., Taniya, T. & Yokoi, T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res. 66, 9090-9098 (2006).
74. Mishra, P.J., Humeniuk, R., Mishra, P.J., Longo-Sorbello, G.S., Banerjee, D. & Bertino, J.R. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc. Natl. Acad. Sci. USA 104, 13513-13518 (2007).
75. Lijinsky, W., Reuber, M.D. & Blackwell, B.N. Liver tumors induced in rats by oral administration of the antihistaminic methapyrilene hydrochloride. Science 209, 817-819 (1980).
76. Steiner, S. et al. Cyclosporine A decreases the protein level of the calcium-binding protein calbindin-D 28kDa in rat kidney. Biochem. Pharmacol. 51, 253-258 (1996).
77. Varela, M.C. et al. Cyclosporine A-induced decrease in calbindin-D 28 kDa in rat kidney but not in cerebral cortex and cerebellum. Biochem. Pharmacol. 55, 2043-2046 (1998).
78. Owen, R.P., Altman, R.B. & Klein, T.E. PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single-drug pharmacogenetics. Hum. Mutat. 29, 456-460 (2008).
79. Molokhia, M. & McKeigue, P. EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. Pharmacogenomics 7, 633-638 (2006).